Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CBX7 | O95931 | 1/20 | 0.40 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.37 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27511771 | 1.00 | BRD4 (0.48) | BRD4KMT2ACBX7CDYLIDO1 | |
| SCHEMBL5674741 | 0.90 | BRD4 (0.47) | BRD4CBX7CDYLIDO1PHGDH | |
| SCHEMBL7471316 | 0.86 | BRD4 (0.49) | BRD4IDO1PHGDHFGFR1FGFR2 | |
| SCHEMBL7471456 | 0.86 | BRD4 (0.49) | BRD4IDO1PHGDHFGFR1FGFR2 | |
| SCHEMBL9283365 | 0.86 | BRD4 (0.49) | BRD4IDO1PHGDHFGFR1FGFR2 | |
| SCHEMBL5674767 | 0.83 | BRD4 (0.41) | BRD4KMT2ANPSR1ALDH1A1L3MBTL1 | |
| SCHEMBL2492829 | 0.82 | KMT2A (0.40) | KMT2ACBX7CDYLIDO1NPSR1 | |
| SCHEMBL2500207 | 0.82 | KMT2A (0.40) | KMT2ACBX7CDYLIDO1NPSR1 | |
| SCHEMBL5675323 | 0.79 | CBX7 (0.47) | KMT2ACBX7CDYLIDO1LMNA | |
| SCHEMBL2492996 | 0.78 | KMT2A (0.42) | KMT2ACBX7CDYLIDO1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119086-B2 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| CN-1224623-C | 1-phenylsulfonyl-1, 3-dihydro-2H-indol-2-one derivatives, their preparation and their therapeutic use | SANOFI ANWANTE (FR) | 2005-10-26 | — | — | CN | disclosed |
| EP-1419150-B1 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2005-04-27 | — | — | EP | disclosed |
| CN-1533387-A | 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use | ����ɳŵ��-����������˾ | 2004-09-29 | — | — | CN | disclosed |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | AVPR2, AVPR1A, AVPR1B | BRD4 2751/4885KMT2A 4309/4885CBX7 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.